RT Journal Article
SR Electronic
T1 A Benchmark of methods for SARS-CoV-2 whole genome sequencing and development of a more sensitive method
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.09.24313595
DO 10.1101/2024.10.09.24313595
A1 Bayega, Anthony
A1 Reiling, Sarah J.
A1 Dubuc, Isabelle
A1 Gravel, Annie
A1 Flamand, Louis
A1 Ragoussis, Jiannis
YR 2024
UL http://medrxiv.org/content/early/2024/10/10/2024.10.09.24313595.abstract
AB The raging COVID-19 pandemic caused by SARS-CoV-2 has so far claimed the lives of 4.6 million people and continues to infect many more. Further, virus evolution has caused mutations that have compromised public health interventions like vaccination regimes and monoclonal antibody and convalescent sera treatments. In response, unprecedented large-scale whole genome viral surveillance approaches have been devised to keep track of the evolution and transmission patterns of the virus within and across populations. Here, we aimed to compare efficiencies of SARS-CoV-2 whole genome sequencing approaches using synthetic SARS-CoV-2 genome and six cell culture SARS-CoV-2 variants titrated to represent samples at high, medium, and low viral load. We found that the ARTIC protocols performed best in terms of PCR amplicon yield returning 67% more amplicons than Entebbe protocol which was the second highest PCR amplicon yielding protocol. ARTIC v4.1 protocol yields were only slightly better than ARTIC v3. Despite yielding the lowest PCR amplicons, the SNAP protocol showed the highest genome completeness using a synthetic genome at high viral titre followed by ARTIC protocols. However, the ARTIC protocols showed highest genome completeness with cell culture SARS-CoV-2 variants across high, medium and low viral titres. ARTIC protocol also performed best in calling the correct lineage among cell culture SARS-CoV-2 variants across different viral titres. We also designed a new method termed ARTIC-Amp which leverages ARTIC protocol and performs a rolling circle amplification to increase yield of amplicons. In a proof-of-principle experiment, this method showed 100% coverage in all four targeted genes across three replicates unlike the ARTIC protocol missed one gene in two of the three replicates. Our results demonstrate the robustness of the ARTIC protocol and propose an improved method that could be useful for samples that routinely have limited SARS-CoV-2 RNA such as wastewater samples.Contribution to the fieldCompeting Interest StatementJR was a member of the MinION Access Program (MAP) and has received free-of-charge flow cells and sequencing kits from Oxford Nanopore Technologies for other projects. JR has had no other financial support from ONT. AB and SJR has received reimbursement for travel costs associated with attending the Nanopore Community meetings organized by Oxford Nanopore Technologies. The rest of the authors do not have competing interests. We received free reagents from Qiagen and Swift Biosciences to test their kits.Funding StatementThis study was supported by the Coronavirus Variants Rapid Response Network (CoVaRR-Net). CoVaRR-Net is funded by an operating grant from the Canadian Institutes of Health Research (CIHR) Instituts de recherchee en sante du Canada (FRN# 175622). JR is funded by a Genome Canada Genomics Technology Platform grant, the Canada Foundation for Innovation (CFI) and the CFI Leaders Opportunity Fund (32557), Compute Canada Resource Allocation Project (WST-164-AB) and Genome Innovation Node (244819).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets presented in this study have been deposited to NCBI SRA with project number PRJNA887365. The individual SRR numbers for each dataset can be found in Supplementary Table 1